BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 29459003)

  • 1. [Knowledge about Biosimilars in Primary Care: a study by the Spanish Society of Primary Care Physicians (SEMERGEN)].
    Micó-Pérez RM; Payares-Herrera C; Palomo-Jiménez PI; Sánchez-Fierro J; Avendaño-Solá C; Llisterri-Caro JL
    Semergen; 2018 Sep; 44(6):380-388. PubMed ID: 29459003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biosimilars: Yes, but with cause knowledge].
    Carballo F
    Semergen; 2018 Sep; 44(6):369-371. PubMed ID: 30195395
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars - terms of use.
    Declerck P; Mellstedt H; Danese S
    Curr Med Res Opin; 2015 Dec; 31(12):2325-30. PubMed ID: 26397731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A survey of pharmacists' knowledge and views of biosimilars in Quebec and France.
    Adé A; Bourdon O; Bussières JF
    Ann Pharm Fr; 2017 Jul; 75(4):267-275. PubMed ID: 28237527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar medical products - licensing, pharmacovigilance and interchangeability.
    Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.
    van Overbeeke E; De Beleyr B; de Hoon J; Westhovens R; Huys I
    BioDrugs; 2017 Oct; 31(5):447-459. PubMed ID: 28929342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical specialists' attitudes to prescribing biosimilars.
    Hemmington A; Dalbeth N; Jarrett P; Fraser AG; Broom R; Browett P; Petrie KJ
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):570-577. PubMed ID: 28233367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
    Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
    Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: what clinicians should know.
    Weise M; Bielsky MC; De Smet K; Ehmann F; Ekman N; Giezen TJ; Gravanis I; Heim HK; Heinonen E; Ho K; Moreau A; Narayanan G; Kruse NA; Reichmann G; Thorpe R; van Aerts L; Vleminckx C; Wadhwa M; Schneider CK
    Blood; 2012 Dec; 120(26):5111-7. PubMed ID: 23093622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.
    Dowlat HA; Kuhlmann MK; Khatami H; Ampudia-Blasco FJ
    Diabetes Obes Metab; 2016 Aug; 18(8):737-46. PubMed ID: 27097592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.
    Castañeda-Hernández G; Sandoval H; Coindreau J; Rodriguez-Davison LF; Pineda C
    Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1035-1044. PubMed ID: 31148288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Physicians' Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing.
    Karateev D; Belokoneva N
    Biomolecules; 2019 Feb; 9(2):. PubMed ID: 30754705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians.
    Barbier L; Vandenplas Y; Simoens S; Declerck P; Vulto AG; Huys I
    J Pharm Policy Pract; 2021 Jun; 14(1):53. PubMed ID: 34158128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nurses' Knowledge and Attitudes towards Biosimilar Medicines as Part of Evidence-Based Nursing Practice-International Pilot Study within the Project Biosimilars Nurses Guide Version 2.0.
    Friganović A; Mędrzycka-Dąbrowska W; Krupa S; Oomen B; Decock N; Stievano A
    Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory challenges with biosimilars: an update from 20 countries.
    Kang HN; Thorpe R; Knezevic I; Casas Levano M; Chilufya MB; Chirachanakul P; Chua HM; Dalili D; Foo F; Gao K; Habahbeh S; Hamel H; Kim GH; Perez Rodriguez V; Putri DE; Rodgers J; Savkina M; Semeniuk O; Srivastava S; Tavares Neto J; Wadhwa M; Yamaguchi T
    Ann N Y Acad Sci; 2021 May; 1491(1):42-59. PubMed ID: 33222245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologicals and biosimilars: safety issues in Europe.
    Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
    Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.